Get the Stockscreener App
4.42
3.76%
0.16
After Hours:
4.42
Olema Pharmaceuticals Inc stock is traded at $4.42, with a volume of 615.56K.
It is up +3.76% in the last 24 hours and down -0.67% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$4.26
Open:
$4.26
24h Volume:
615.56K
Relative Volume:
0.62
Market Cap:
$277.43M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.0558
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+29.62%
1M Performance:
-0.67%
6M Performance:
-64.09%
1Y Performance:
-58.73%
1-Day Range:
$4.215
$4.44
1-Week Range:
$3.30
$4.44
52-Week Range:
$2.86
$16.62
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
4.42 | 277.43M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Franklin Resources Inc. Has $1.60 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Vanguard Group Inc. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Alliancebernstein L.P. Has $1.83 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
American Century Companies Inc. Reduces Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Wellington Management Group LLP Purchases 522,799 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
KLP Kapitalforvaltning AS Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) - Yahoo Finance
Wellington Management Group LLP Has $8.84 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - The AM Reporter
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by Schroder Investment Management Group - MarketBeat
Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market - Seeking Alpha
Pictet Asset Management Holding SA Has $10.98 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
HighTower Advisors LLC Invests $510,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
10,352 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Bought by Teacher Retirement System of Texas - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Olema Expands Team: 5 Key Hires Receive Equity Compensation Package - Stock Titan
Top Premarket Decliners - MarketScreener
Insiders Could Have Profited By Holding onto Olema Pharmaceuticals Shares Despite 13% Drop - simplywall.st
JPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00 - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $3.86 By Investing.com - Investing.com South Africa
Olema Pharmaceuticals stock hits 52-week low at $3.86 - Investing.com
HighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
JPMorgan Chase & Co. Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00 - Defense World
Pier Capital LLC Acquires New Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Bank of New York Mellon Corp Trims Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology to Present Preclinical Data for OP-3136, a - GlobeNewswire
Victory Capital Management Inc. Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Cancer Breakthrough: New Drug Shows Powerful Anti-Tumor Effects in Prostate, Ovarian, Lung Cancers - Stock Titan
What is Lifesci Capital's Estimate for OLMA FY2025 Earnings? - MarketBeat
What is HC Wainwright's Forecast for OLMA FY2029 Earnings? - MarketBeat
Olema Pharmaceuticals' (OLMA) "Outperform" Rating Reiterated at Oppenheimer - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
HC Wainwright Issues Optimistic Estimate for OLMA Earnings - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Victory Capital Management Inc. Sells 758,412 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - Defense World
FY2025 EPS Estimate for Olema Pharmaceuticals Cut by Analyst - Defense World
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):